Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

User applied topical Minoxidil 5% and Finasteride 0.1% daily, with rosemary oil weekly, and saw initial baby hair growth. They plan to add derma stamping and Redensyl serum.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

A user experienced facial swelling while taking spironolactone for androgenic alopecia, despite its diuretic properties. They are unsure about increasing the dose due to this side effect.

Rotenone, a natural plant extract, may promote hair growth by increasing LDH activity and blocking MPC in the scalp, but it carries risks due to its toxicity. The suggested formulation includes Barbasco extract, DMSO, propylene glycol or PEG-400, ethanol, and a carrier oil.

The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.

The conversation is a satirical expression of frustration over hair loss, mentioning treatments like spironolactone, microneedling, and topical applications, with references to various hair loss products and personalities in the community.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation is about finding a source for topical valproic acid for hair regrowth. The user mentions PP405 and the unavailability of products from certain suppliers.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

A user shared a 5-month progress picture showing hair regrowth from taking 1mg of finasteride daily. Another user reported significant hair regrowth and no side effects after 12 years on finasteride.

Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

Hair loss treatments RU and topical spironolactone were compared. No specific results or conclusions were provided.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.

A female user is considering using RU58841 with minoxidil 2.5% to reduce side effects like facial hair from minoxidil 5%, while also using copper peptides and a hair serum. Other users discuss alternative treatments like spironolactone, alfatradiol, and the side effects of finasteride.

Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.

Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.

The user is experiencing significant hair growth improvement after 5 months using finasteride, topical minoxidil, microneedling, and ketoconazole shampoo, with no side effects except less body hair. The routine includes daily oral finasteride, twice-daily topical minoxidil, weekly microneedling, and starting ketoconazole shampoo.

Minoxidil, PRP, low-level light therapy, stem cell therapy, mesotherapy, Acell, and microneedling are discussed as treatments for thickening fine hairs in NW5 hair loss sufferers. A hair transplant may be necessary for significant improvement.

Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.

The user shared their 5-month progress using Minoxidil, finasteride, and weekly dermastamping, noting improvements in their hairline and crown. They also use a saw palmetto shampoo and have not experienced shedding yet.

Gene editing for hair loss is not yet viable due to technological and economic challenges. Current treatments like Minoxidil, finasteride, and hair transplants remain the most practical options.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Injections of follistatin and growth factors can improve hair growth. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.